ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Soliris (Eculizumab) Injection Approved to Treat Neuromyelitis Optica Spectrum Disorder
July 01, 2019Soliris (Eculizumab) Injection Approved to Treat Neuromyelitis Optica Spectrum Disorder. -
FDA approves first treatment for neuromyelitis optica spectrum disorder, a rare autoimmune disease of the central nervous system
July 01, 2019FDA approves first treatment for neuromyelitis optica spectrum disorder, a rare autoimmune disease of the central nervous system. -
Alexion Receives FDA Approval of Soliris (eculizumab) for the Treatment of Adults with Neuromyelitis Optica Spectrum Disorder
June 28, 2019Alexion Receives FDA Approval of Soliris (eculizumab) for the Treatment of Adults with Neuromyelitis Optica Spectrum Disorder. -
Alexion aims for fourth rare disease use for blockbuster Soliris
February 27, 2019The FDA has granted a fast review for Alexion Pharmaceuticals’ filing for its Soliris, as a treatment for a rare neurological disease that leads to worsening disability, blindness, paralysis, and possibly early death. -
Chugai preps filings for IL-6 drug in rare disease, chasing Soliris
December 20, 2018Chugai has the positive phase 3 data it needs to file IL-6-targeting antibody satralizumab for approval in neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease, next year.
Pharma Sources Insight January 2025
